Home

search

Subjectguide
Journals
Books / Serials / Multimedia
Services
Services

Login for Subscribers
Logout

Sitemap
Help
Contacts


Logo






Vol. 27, No. 4, 2004   

Free Abstract     Article (References)     Article (PDF 514 KB)     

Original Paper

Blockade of Endothelin Receptors Attenuates End-Organ Damage in Homozygous Hypertensive Ren-2 Transgenic Rats
Pavel Dvorcaronáka,e, Herbert J. Kramerb, Angela Bäckerb, Jan Malýa, Libor Kopkana, Ivana Vanecaronccaronkováa, Zdena Vernerováa,f, Martin Opoccaronenskýa, Vladimír Tesarcaronc, Michael Baderd, Detlev Gantend, Jan Jandae, Ludecaronk Ccaronervenkaa

aCenter for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic;
bSection of Nephrology, Medical Policlinic, Department of Medicine, University of Bonn, Bonn, Germany;
cDepartment of Nephrology, 1st Department of Medicine, 1st Medical Faculty, Charles University, Prague, Czech Republic;
dMax Delbrück Center for Molecular Medicine and Franz Volhard Clinic, Berlin-Buch, Germany;
eDepartment of Pediatrics, 2nd Medical Faculty, and
fDepartment of Pathology, 3rd Medical Faculty, Charles University, Prague, Czech Republic

Address of Corresponding Author

Kidney & Blood Pressure Research 2004;27:248-258 (DOI: 10.1159/000080052)


 goto top of page Key Words

  • Hypertension
  • Endothelin
  • Renin-angiotensin system
  • Bosentan
  • End-organ damage

 goto top of page Abstract

Background/Aims: A growing body of evidence suggests that the interplay between the endothelin (ET) and the renin-angiotensin systems (RAS) plays an important role in the development of the malignant phase of hypertension. The present study was performed to evaluate the role of an interaction between ET and RAS in the development of hypertension and hypertension-associated end-organ damage in homozygous male transgenic rats harboring the mouse Ren-2 renin gene (TGRs) under conditions of normal-salt (NS, 0.45% NaCl) and high-salt (HS, 2% NaCl) intake. Methods: Twenty-eight-day-old homozygous male TGRs and age-matched transgene-negative male normotensive Hannover Sprague-Dawley (HanSD) rats were randomly assigned to groups with NS or HS intake. Nonselective ETA/B receptor blockade was achieved with bosentan (100 mg/kg/day). Systolic blood pressure (BP) was measured in conscious animals by tail plethysmography. Rats were placed into metabolic cages to determine proteinuria and clearance of endogenous creatinine. At the end of the experiment the final arterial BP was measured directly in anesthetized rats. Kidneys were taken for morphological examination. Results: All male HanSD fed either the NS or HS diet exhibited a 100% survival rate until 180 days of age (end of experiment). The survival rate in untreated homozygous male TGRs fed the NS diet was 41%, which was markedly improved by treatment with bosentan to 88%. The HS diet reduced the survival rate in homozygous male TGRs to 10%. The survival rate in homozygous male TGRs on the HS diet was significantly improved by bosentan to 69%. Treatment with bosentan did not influence either the course of hypertension or the final levels of BP in any of the experimental groups of HanSD rats or TGRs. Although the ET-1 content in the renal cortex did not differ between HanSD rats and TGRs, ET-1 in the left heart ventricle of TGRs fed the HS diet was significantly higher compared with all other groups. Administration of bosentan to homozygous male TGRs fed either the NS or HS diet markedly reduced proteinuria, glomerulosclerosis and attenuated the development of cardiac hypertrophy compared with untreated TGR. Conclusions: Our data show that nonselective ETA/B receptor blockade markedly improves the survival rate and ameliorates end-organ damage in homozygous male TGRs without significantly lowering BP.

Copyright © 2004 S. Karger AG, Basel


 goto top of page Author Contacts

Ludecaronk Ccaronervenka, MD, PhD
Center for Experimental Medicine, Institute for Clinical and Experimental Medicine
1958/9 Vídencaronská
CZ-140 21 Prague 4 (Czech Republic)
Tel./Fax +420 2417 21 666, E-Mail luce@medicon.cz


 goto top of page Article Information

Accepted: May 28, 2004
Published online: August 2, 2004
Number of Print Pages : 11
Number of Figures : 5, Number of Tables : 3, Number of References : 48

 
Journal Home
Journal Content
Guidelines
Editorial Board
Aims and Scope
Subscriptions
Medline Abstract (ID 15286437)
Download Citation
Cited In



New KBPR Award
More information: PDF

This journal is part of the third subject package of the Karger

Journal Archive Collection

Information on packages (PDF)
Free sample issues



For non-native English speakers and international authors who would like assistance with their writing before submission, we suggest American Journal Experts for their scientific editing service.




copyright  © 2010 S. Karger AG, Basel